Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting.
Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting.
复制标题
DOI：
10.1016/j.amepre.2020.10.022
复制
发表时间：
2021-03
影响因子：
5.5
通讯作者：
Lee BY
中科院分区：
文献类型：
--
作者：
Bartsch SM;O'Shea KJ;Wedlock PT;Ferguson MC;Siegmund SS;Lee BY
With norovirus vaccine candidates currently under development, now is the time to identify the vaccine characteristics and implementation thresholds at which vaccination becomes cost effective and cost saving in a community setting. In 2020, a norovirus transmission, clinical, and economics computational simulation model representing different U.S. population segments was developed to simulate the spread of norovirus and the potential impact of vaccinating children aged <5 years and older adults (aged ≥65 years). Compared with no vaccination, vaccinating preschool-aged children averted 8%–72% of symptomatic norovirus cases in a community, whereas vaccinating older adults averted 2%–29% of symptomatic cases (varying with vaccine efficacy [25%–75%] and vaccination coverage [10%–80%]). Vaccination with a 25% vaccine efficacy was cost effective (incremental cost–effectiveness ratio ≤$50,000 per quality-adjusted life year) when vaccination cost ≤$445 and cost saving at ≤$370 when vaccinating preschool-aged children and ≤$42 and ≤$30, respectively, when vaccinating older adults. With a 50% vaccine efficacy, vaccination was cost effective when it cost ≤$1,190 and cost saving at ≤$930 when vaccinating preschool-aged children and ≤$110 and ≤$64, respectively, when vaccinating older adults. These cost thresholds (cost effective and cost saving, respectively) further increased with a 75% vaccine efficacy to ≤$1,600 and ≤$1,300 for preschool-aged children and ≤$165 and ≤$100 for older adults. This study outlines thresholds at which a norovirus vaccine would be cost effective and cost saving in the community when vaccinating children aged <5 years and older adults. Establishing these thresholds can help provide decision makers with targets to consider when developing and implementing a norovirus vaccine.
登录
查看更多内容
影响因子：
6.2
作者：
Mattison CP;Cardemil CV;Hall AJ
通讯作者：
Hall AJ
影响因子：
5.5
作者：
Lee, Bruce Y.;Burke, Donald S.
通讯作者：
Burke, Donald S.
DOI：
10.1093/infdis/jix572
发表时间：
2018-01-30
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Leroux-Roels G;Cramer JP;Mendelman PM;Sherwood J;Clemens R;Aerssens A;De Coster I;Borkowski A;Baehner F;Van Damme P
通讯作者：
Van Damme P
影响因子：
3.8
作者：
Steele, Molly K.;Remais, Justin V.;Gambhir, Manoj;Glasser, John W.;Handel, Andreas;Parashar, Umesh D.;Lopman, Benjamin A.
通讯作者：
Lopman, Benjamin A.
影响因子：
5.5
作者：
Bartsch, Sarah M.;Lopman, Benjamin A.;Lee, Bruce Y.
通讯作者：
Lee, Bruce Y.